News & Insights
Featured
Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.
Mostafa Kamal, chief executive officer at Prime Therapeutics, shares why the key question in the drug pricing debate is not just where health care value is created, but whether it ultimately reaches the patients, employers and health plans paying for care.
Library
Prime supports TrumpRx pricing as another way to help members compare options and find the lowest available prescription drug price
Prime’s curated platform helps plans and employers navigate point-solution complexity and deliver a more connected experience for members
Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.
As assistant vice president of health outcomes, Gleason leads research into healthcare access, costs and outcomes, helping guide benefit strategies for payers and providers
Mostafa Kamal, chief executive officer at Prime Therapeutics, shares why the key question in the drug pricing debate is not just where health care value is created, but whether it ultimately reaches the patients, employers and health plans paying for care.
Login Portals
Compliance / Legal
Company
